MX2023004516A - Uso de pridopidina y analogos para el tratamiento de la ansiedad y la depresion. - Google Patents

Uso de pridopidina y analogos para el tratamiento de la ansiedad y la depresion.

Info

Publication number
MX2023004516A
MX2023004516A MX2023004516A MX2023004516A MX2023004516A MX 2023004516 A MX2023004516 A MX 2023004516A MX 2023004516 A MX2023004516 A MX 2023004516A MX 2023004516 A MX2023004516 A MX 2023004516A MX 2023004516 A MX2023004516 A MX 2023004516A
Authority
MX
Mexico
Prior art keywords
depression
anxiety
pridopidine
analogs
treatment
Prior art date
Application number
MX2023004516A
Other languages
English (en)
Inventor
Michael Hayden
Michal Geva
Original Assignee
Prilenia Neurotherapeutics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US17/074,901 external-priority patent/US20210093622A1/en
Priority claimed from US17/498,075 external-priority patent/US20220023280A1/en
Application filed by Prilenia Neurotherapeutics Ltd filed Critical Prilenia Neurotherapeutics Ltd
Publication of MX2023004516A publication Critical patent/MX2023004516A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/451—Non condensed piperidines, e.g. piperocaine having a carbocyclic group directly attached to the heterocyclic ring, e.g. glutethimide, meperidine, loperamide, phencyclidine, piminodine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/452—Piperidinium derivatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Abstract

La invención proporciona una composición farmacéutica que comprende pridopidina o una sal farmacéuticamente aceptable de la misma y al menos uno de los compuestos 1-8 o una sal farmacéuticamente aceptable de los mismos para usarse en reducir la ansiedad, la depresión o una combinación de las mismas en un sujeto que lo necesite, en donde la composición está adaptada para ser administrable al sujeto en una cantidad eficaz para reducir la ansiedad, la depresión o una combinación de las mismas en el sujeto.
MX2023004516A 2020-10-20 2021-10-20 Uso de pridopidina y analogos para el tratamiento de la ansiedad y la depresion. MX2023004516A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US17/074,901 US20210093622A1 (en) 2016-09-15 2020-10-20 Use of pridopidine for the treatment of anxiety and depression
US17/498,075 US20220023280A1 (en) 2014-06-30 2021-10-11 Analogs of pridopidine, their preparation and use
PCT/IL2021/051243 WO2022084999A1 (en) 2020-10-20 2021-10-20 Use of pridopidine and analogs for the treatment of anxiety and depression

Publications (1)

Publication Number Publication Date
MX2023004516A true MX2023004516A (es) 2023-05-04

Family

ID=81290207

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2023004516A MX2023004516A (es) 2020-10-20 2021-10-20 Uso de pridopidina y analogos para el tratamiento de la ansiedad y la depresion.

Country Status (8)

Country Link
EP (1) EP4232033A1 (es)
JP (1) JP2023545846A (es)
KR (1) KR20230091153A (es)
AU (1) AU2021366505A1 (es)
CA (1) CA3192542A1 (es)
IL (1) IL302261A (es)
MX (1) MX2023004516A (es)
WO (1) WO2022084999A1 (es)

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE0401465D0 (sv) * 2004-06-08 2004-06-08 Carlsson A Research Ab New substituted piperdines as modulators of dopamine neurotransmission
TW201613859A (en) * 2014-06-30 2016-04-16 Teva Pharma Analogs of PRIDOPIDINE, their preparation and use
CA3036842A1 (en) * 2016-09-15 2018-03-22 Prilenia Therapeutics Development Ltd. Use of pridopidine for the treatment of anxiety and depression
BR112021024744A2 (pt) * 2019-06-12 2022-03-22 Prilenia Neurotherapeutics Ltd Método para melhorar, manter ou reduzir o comprometimento da capacidade funcional e função motora de um paciente humano com doença de huntington

Also Published As

Publication number Publication date
WO2022084999A1 (en) 2022-04-28
EP4232033A1 (en) 2023-08-30
KR20230091153A (ko) 2023-06-22
CA3192542A1 (en) 2022-04-28
JP2023545846A (ja) 2023-10-31
IL302261A (en) 2023-06-01
AU2021366505A1 (en) 2023-06-01

Similar Documents

Publication Publication Date Title
NI201100147A (es) Métodos para tratar infartos agudos de miocardio y trastornos relacionados.
PH12015502691A1 (en) Use of high dose pridopidine for treating huntington's disease
JP2014139220A5 (es)
MX2022003072A (es) Uso de pridopidina para el tratamiento de la disminucion funcional.
MX2019012884A (es) Terapia de combinacion.
PH12020551597A1 (en) Treatment of hidradenitis suppurativa using jak inhibitors
BR112012022064A2 (pt) tratamento de artrite lúpica usando laquinimod
SG10201810401RA (en) Pharmaceutical combinations for treating cancer
NZ602510A (en) Treatment of lupus nephritis using laquinimod
BR112014015482A2 (pt) compostos carbamato de fenila para uso no alívio ou tratamento de dor e dor neuropática
MX2023005984A (es) Nuevos agentes antivirales derivados de la espiropirrolidina.
SG10201810404XA (en) Combination comprising a glucocorticoid and edo-s101
PH12021550713A1 (en) Medicament for the treatment of chronic cough
PH12019500328A1 (en) Aza-indazole compounds for use in tendon and/or ligament injuries
PH12019500618A1 (en) Pharmaceutical composition and method for treatment of non-alcoholic fatty liver disease
MX2022015629A (es) Uso de vibegron para tratar vejiga sobreactiva.
MX2022007911A (es) Procedimiento de tratamiento de una infeccion virica usando un agonista de tlr7.
PH12019502510A1 (en) Pharmaceutical composition and pharmaceutical dosage form comprising (e)-4-(2-(aminomethyl)-3-fluoroallyloxy)-n-tert-butylbenzamide, process for their preparation, methods for treating and uses thereof
MX2023004516A (es) Uso de pridopidina y analogos para el tratamiento de la ansiedad y la depresion.
CL2021003303A1 (es) Tratamiento para sinucleinopatías.
PL423672A1 (pl) Kompozycja farmaceutyczna zawierająca zebularynę oraz środek leczniczy do regeneracji ran
MX2022012001A (es) Tratamiento preventivo de la migra?a.
MX2022011651A (es) Composicion farmaceutica para tratamiento de diabetes.
EA202193276A1 (ru) Способы лечения холангиокарциномы
MX2020001217A (es) Metodos de tratamiento de sintomas de gastroparesia usando velusetrag.